Allergic rhinitis and its pharmacology

Yousuf M. Al Suleimani, Michael J A Walker

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The pathophysiology of allergic rhinitis and its drug treatment is reviewed. Special emphasis is placed upon potential new treatments. Allergic rhinitis is characterized by allergen(s), symptoms (sneezing, itching, rhinorrhea, nasal congestion and nasal hypersensitivity), and signs such as invasion of nasal mucosa by inflammatory cells. Such pathological changes are due to inflammatory responses mediated by way of allergen-immunoglobulin E (IgE)-cell complex formation. The complexity of the disease and the multiple pathways involved offer many targets for drug treatment, but to date no single drug is totally effective. This review summarizes the current knowledge of allergic rhinitis, its prevalence, pathophysiology and experimental and clinical treatments. In the search for new drugs, different experimental animal models of allergic rhinitis are required. As a result the models have also been reviewed. Furthermore, particular aspects of the pathophysiology of allergic rhinitis are discussed in greater detail including the immune cells involved in the mediation of the disease, chemical mediators, their actions, and the receptors on which they act. Therapy, particularly that with current drugs, targets many of the known mediators and some of the cellular processes with varying success. Other drugs, for example, vasoconstrictors given to reduce rhinorrhea, provide symptomatic relief by counteracting symptoms. Since the incidence of allergic rhinitis is prevalent and growing in many parts of the world and current treatments are not ideal, it is important to continue to study the pharmacology of this disease as part of a search for better drugs.

Original languageEnglish
Pages (from-to)233-260
Number of pages28
JournalPharmacology and Therapeutics
Volume114
Issue number3
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Pharmacology
Pharmaceutical Preparations
Nose
Allergens
Sneezing
Nasal Mucosa
Vasoconstrictor Agents
Pruritus
Immunoglobulin E
Allergic Rhinitis
Hypersensitivity
Animal Models
Incidence
Therapeutics

Keywords

  • Allergic rhinitis
  • Pathophysiology
  • Rhinitis mediators
  • Rhinitis pharmacology
  • Treatment of rhinitis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Allergic rhinitis and its pharmacology. / Al Suleimani, Yousuf M.; Walker, Michael J A.

In: Pharmacology and Therapeutics, Vol. 114, No. 3, 06.2007, p. 233-260.

Research output: Contribution to journalArticle

Al Suleimani, Yousuf M. ; Walker, Michael J A. / Allergic rhinitis and its pharmacology. In: Pharmacology and Therapeutics. 2007 ; Vol. 114, No. 3. pp. 233-260.
@article{c25292f4f9f448f8b6e5620fc526b811,
title = "Allergic rhinitis and its pharmacology",
abstract = "The pathophysiology of allergic rhinitis and its drug treatment is reviewed. Special emphasis is placed upon potential new treatments. Allergic rhinitis is characterized by allergen(s), symptoms (sneezing, itching, rhinorrhea, nasal congestion and nasal hypersensitivity), and signs such as invasion of nasal mucosa by inflammatory cells. Such pathological changes are due to inflammatory responses mediated by way of allergen-immunoglobulin E (IgE)-cell complex formation. The complexity of the disease and the multiple pathways involved offer many targets for drug treatment, but to date no single drug is totally effective. This review summarizes the current knowledge of allergic rhinitis, its prevalence, pathophysiology and experimental and clinical treatments. In the search for new drugs, different experimental animal models of allergic rhinitis are required. As a result the models have also been reviewed. Furthermore, particular aspects of the pathophysiology of allergic rhinitis are discussed in greater detail including the immune cells involved in the mediation of the disease, chemical mediators, their actions, and the receptors on which they act. Therapy, particularly that with current drugs, targets many of the known mediators and some of the cellular processes with varying success. Other drugs, for example, vasoconstrictors given to reduce rhinorrhea, provide symptomatic relief by counteracting symptoms. Since the incidence of allergic rhinitis is prevalent and growing in many parts of the world and current treatments are not ideal, it is important to continue to study the pharmacology of this disease as part of a search for better drugs.",
keywords = "Allergic rhinitis, Pathophysiology, Rhinitis mediators, Rhinitis pharmacology, Treatment of rhinitis",
author = "{Al Suleimani}, {Yousuf M.} and Walker, {Michael J A}",
year = "2007",
month = "6",
doi = "10.1016/j.pharmthera.2007.01.012",
language = "English",
volume = "114",
pages = "233--260",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Allergic rhinitis and its pharmacology

AU - Al Suleimani, Yousuf M.

AU - Walker, Michael J A

PY - 2007/6

Y1 - 2007/6

N2 - The pathophysiology of allergic rhinitis and its drug treatment is reviewed. Special emphasis is placed upon potential new treatments. Allergic rhinitis is characterized by allergen(s), symptoms (sneezing, itching, rhinorrhea, nasal congestion and nasal hypersensitivity), and signs such as invasion of nasal mucosa by inflammatory cells. Such pathological changes are due to inflammatory responses mediated by way of allergen-immunoglobulin E (IgE)-cell complex formation. The complexity of the disease and the multiple pathways involved offer many targets for drug treatment, but to date no single drug is totally effective. This review summarizes the current knowledge of allergic rhinitis, its prevalence, pathophysiology and experimental and clinical treatments. In the search for new drugs, different experimental animal models of allergic rhinitis are required. As a result the models have also been reviewed. Furthermore, particular aspects of the pathophysiology of allergic rhinitis are discussed in greater detail including the immune cells involved in the mediation of the disease, chemical mediators, their actions, and the receptors on which they act. Therapy, particularly that with current drugs, targets many of the known mediators and some of the cellular processes with varying success. Other drugs, for example, vasoconstrictors given to reduce rhinorrhea, provide symptomatic relief by counteracting symptoms. Since the incidence of allergic rhinitis is prevalent and growing in many parts of the world and current treatments are not ideal, it is important to continue to study the pharmacology of this disease as part of a search for better drugs.

AB - The pathophysiology of allergic rhinitis and its drug treatment is reviewed. Special emphasis is placed upon potential new treatments. Allergic rhinitis is characterized by allergen(s), symptoms (sneezing, itching, rhinorrhea, nasal congestion and nasal hypersensitivity), and signs such as invasion of nasal mucosa by inflammatory cells. Such pathological changes are due to inflammatory responses mediated by way of allergen-immunoglobulin E (IgE)-cell complex formation. The complexity of the disease and the multiple pathways involved offer many targets for drug treatment, but to date no single drug is totally effective. This review summarizes the current knowledge of allergic rhinitis, its prevalence, pathophysiology and experimental and clinical treatments. In the search for new drugs, different experimental animal models of allergic rhinitis are required. As a result the models have also been reviewed. Furthermore, particular aspects of the pathophysiology of allergic rhinitis are discussed in greater detail including the immune cells involved in the mediation of the disease, chemical mediators, their actions, and the receptors on which they act. Therapy, particularly that with current drugs, targets many of the known mediators and some of the cellular processes with varying success. Other drugs, for example, vasoconstrictors given to reduce rhinorrhea, provide symptomatic relief by counteracting symptoms. Since the incidence of allergic rhinitis is prevalent and growing in many parts of the world and current treatments are not ideal, it is important to continue to study the pharmacology of this disease as part of a search for better drugs.

KW - Allergic rhinitis

KW - Pathophysiology

KW - Rhinitis mediators

KW - Rhinitis pharmacology

KW - Treatment of rhinitis

UR - http://www.scopus.com/inward/record.url?scp=34249731992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249731992&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2007.01.012

DO - 10.1016/j.pharmthera.2007.01.012

M3 - Article

C2 - 17433446

AN - SCOPUS:34249731992

VL - 114

SP - 233

EP - 260

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -